Related Experiment Video
Updated: Jun 3, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Treating soft tissue sarcomas with adjuvant chemotherapy
Anna Patrikidou1, Julien Domont, Angela Cioffi
1Department of Medicine, Institut Gustave Roussy, Villejuif, France.
Current Treatment Options in Oncology
|March 9, 2011
Summary
Adjuvant chemotherapy for soft tissue sarcoma (STS) does not consistently improve survival, though it may benefit select high-grade or incompletely resected cases. Further research is needed to identify specific patient subgroups who benefit from chemotherapy.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Soft tissue sarcoma (STS) treatment relies on surgery, with radiotherapy often used for localized, resectable tumors.
- Despite surgical advances, over half of patients develop advanced or metastatic disease.
- Current chemotherapy options for metastatic STS are limited, with doxorubicin and ifosfamide showing some activity.
Purpose of the Study:
- To evaluate the controversial role of adjuvant chemotherapy in improving survival outcomes for localized soft tissue sarcoma.
- To identify potential subpopulations of patients who may benefit from adjuvant chemotherapy.
- To inform future clinical trial designs for adjuvant therapy in STS.
Main Methods:
- Review of existing randomized trials and meta-analyses on adjuvant chemotherapy for soft tissue sarcoma.
- Analysis of prognostic and predictive factors influencing treatment response.
- Examination of the impact of chemotherapy on local recurrence, metastasis, and overall survival.
Main Results:
- Adjuvant chemotherapy has not reproducibly demonstrated a significant benefit in overall or relapse-free survival for unselected STS patients.
- Some trials suggest a reduced risk of local recurrence with adjuvant chemotherapy, but without a survival gain.
- Specific subgroups, such as those with grade 3 STS or R1 resection, may potentially benefit.
Conclusions:
- Routine adjuvant chemotherapy is not recommended for high-grade STS.
- Adjuvant chemotherapy may be considered for patients with grade 3 STS or R1 resection.
- Future trials must incorporate histological subtypes and biomarkers to personalize adjuvant therapy for STS.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...